Update in adrenocortical carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages 4551-4564

  Fassnacht, Martin ^a,b   Kroiss, Matthias ^b   Allolio, Bruno ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; CAPECITABINE; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DOVITINIB; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GEFITINIB; GEMCITABINE; IODINE 131; KI 67 ANTIGEN; LINSITINIB; METOMIDATE; METOMIDATE I 131; MITOTANE; PACLITAXEL; SORAFENIB; STEROIDOGENIC FACTOR 1; STREPTOZOCIN; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; WNT PROTEIN;

ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ADVANCED CANCER; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG TARGETING; DRUG TREATMENT FAILURE; ENDOCRINE FUNCTION TEST; EXTERNAL BEAM RADIOTHERAPY; FINE NEEDLE ASPIRATION BIOPSY; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; RADICAL RESECTION; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ULTRASOUND; VERTIGO;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLANDS; ADRENOCORTICAL CARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DECISION TREES; HUMANS; LYMPH NODE EXCISION; MITOTANE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; SALVAGE THERAPY;

EID: 84889853637     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3020     Document Type: Article

References (140)

1. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: Clinical update. J Clin Endocrinol Metab. 2006;91:2027-2037
2. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872-878
3. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: A population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49:2579-2586
4. Custódio G, Komechen H, Figueiredo FR, Fachin ND, Pianovski MA, Figueiredo BC. Molecular epidemiology of adrenocortical tumors in southern Brazil. Mol Cell Endocrinol. 2012;351:44-51
5. Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol. 2003;162:521-531
6. de Fraipont F, El Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab. 2005;90: 1819-1829
7. Gicquel C, Bertagna X, Gaston V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001;61:6762-6767
8. Berthon A, Sahut-Barnola I, Lambert-Langlais S, et al. Constitutive β-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet. 2010;19:1561-1576
9. Gaujoux S, Grabar S, Fassnacht M, et al. β-Catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res. 2011;17:328-336
10. Gicquel C, Bertagna X, Schneid H, et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-2 gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab. 1994;78:1444-1453
11. Barlaskar FM, Spalding AC, Heaton JH, et al. Preclinical targeting of the type 1insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab. 2009;94:204-212
12. Tissier F, Cavard C, Groussin L, et al. Mutations of β-catenin in adrenocortical tumors: Activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65:7622-7627
13. 53 and β-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010;70:8276-8281
14. Gaujoux S, Tissier F, Groussin L, et al. Wnt/β-catenin and 3', 5' cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic β-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab. 2008;93:4135-4140
15. Bonnet S, Gaujoux S, Launay P, et al. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: A study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol Metab. 2011;96:E419-E426
16. Heaton JH, Wood MA, Kim AC, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol. 2012;181:1017-1033
17. Drelon C, Berthon A, Ragazzon B, et al. Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS One. 2012;7:e44171
18. Sbiera S, Schmull S, Assie G, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010;95:E161-E171
19. Almeida MQ, Soares IC, Ribeiro TC, et al. Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults. J Clin Endocrinol Metab. 2010;95:1458-1462
20. Lalli E. Adrenocortical development and cancer: focus on SF-1. J Mol Endocrinol. 2010;44:301-307
21. Duregon E, Volante M, Giorcelli J, Terzolo M, Lalli E, Papotti M. Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: A validation study focusing on clinical and pathologic correlates. Hum Pathol. 2013;44:822-828
22. Doghman M, Cazareth J, Douguet D, Madoux F, Hodder P, Lalli E. Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. J Clin Endocrinol Metab. 2009;94:2178-2183
23. Herrmann LJ, Heinze B, Fassnacht M, et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97:E476-E485
24. Raymond VM, Else T, Everett JN, Long JM, Gruber SB, Hammer GD. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:E119-E125
25. Raymond VM, Everett JN, Furtado LV, et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol. 2013; 31:3012-3018
26. de Reyniès A, Assié G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 2009;27:1108-1115
27. Giordano TJ, Kuick R, Else T, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res. 2009;15:668-676
28. Simon DP, Giordano TJ, Hammer GD. Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma. Clin Cancer Res. 2012;18:2452-2464
29. Tömböl Z, Szabó PM, Molnár V, et al. Integrative molecular bioinformatics study ofhumanadrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer. 2009;16:895-906
30. Zsippai A, Szabó DR, Tömböl Z, et al. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: A microarray study. Pharmacogenomics. 2012;13:1351-1361
31. Caramuta S, Lee L, OzataDM,et al. Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma. Endocr Relat Cancer. 2013;20:551-564
32. Chabre O, Libé R, Assie G, et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr Relat Cancer. 2013;20:579-594
33. Fonseca AL, Kugelberg J, Starker LF, et al. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer. 2012;51:949-960
34. Barreau O, Assié G, Wilmot-Roussel H, et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. J Clin Endocrinol Metab. 2013;98:E174-E184
35. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356:601-610
36. Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27:4619-4629
37. Nieman LK. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab. 2010;95:4106-4113
38. Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol. 2011;60:1055-1065
39. Berruti A, Baudin E, Gelderblom H, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol. 2012;23(suppl 7):vii131-138
40. Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011;96:3775-3784
41. Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR Am J Roentgenol. 2010;194:1450-1460
42. Young WF Jr. Conventional imaging in adrenocortical carcinoma: update and perspectives. Horm Cancer. 2011;2:341-347
43. Petersenn S, Richter P, Broemel T, et al. CT criteria for adrenal cancer - analysis of the German ACC registry. Exp Clin Endocrinol Diabetes. 2013;121:OP8-48
44. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005; 234:479-485
45. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: A comparison of different methods. Endocr Relat Cancer. 2007;14:587-599
46. Park BK, Kim CK, Kim B, Lee JH. Comparison of delayed enhanced CT and chemical shiftMRfor evaluating hyperattenuating incidental adrenal masses. Radiology. 2007;243:760-765
47. Zhang HM, Perrier ND, Grubbs EG, et al. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies. Clin Radiol. 2012;67:38 - 46
48. Bauditz J, Quinkler M, Beyersdorff D, Wermke W. Improved detection of hepatic metastases of adrenocortical cancer by contrastenhanced ultrasound. Oncol Rep. 2008;19:1135-1139
49. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by usingFDGPET: A systematic review and meta-analysis of diagnostic test performance. Radiology. 2011;259:117-126
50. Deandreis D, Leboulleux S, Caramella C, Schlumberger M,Baudin E. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer. 2011;2:354-362
51. Hahner S, Sundin A. Metomidate-based imaging of adrenal masses. Horm Cancer. 2011;2:348-353
52. Kreissl MC, Schirbel A, Fassnacht M, et al. [123I]Iodometomidate imaging in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:2755-2764
53. Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:2665-2671
54. Leboulleux S, Dromain C, Bonniaud G, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: A prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006;91:920-925
55. Williams A, Hammer GD, Else T. Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome. Endocr Rev. 2013; 34:MON-1
56. Johanssen S, Hahner S, Saeger W, et al. Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch Arztebl Int. 2010;107:885-891
57. Sasano H, Suzuki T, Moriya T. Recent advances in histopathologyand immunohistochemistry of adrenocortical carcinoma. Endocr Pathol. 2006;17:345-354
58. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009;40:757-768
59. Volante M, Bollito E, Sperone P, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology. 2009;55:535-543
60. Papotti M, Libè R, Duregon E, Volante M, Bertherat J, Tissier F. The Weiss score and beyond - histopathology for adrenocortical carcinoma. Horm Cancer. 2011;2:333-340
61. Tissier F, Aubert S, Leteurtre E, et al. Adrenocortical tumors: Improving the practice of the Weiss system through virtual microscopy: A national program of the French Network INCa-COMETE. Am J Surg Pathol. 2012;36:1194-1201
62. Duregon E, Fassina A, Volante M, et al. The reticulin algorithm for adrenocortical tumor diagnosis: A multicentric validation study on 245 unpublished cases. Am J Surg Pathol. 2013;37:1433-1440
63. Beuschlein F, Obracay J, Saeger W, et al. Prognostic value of histological markers in localized adrenocortical carcinoma after complete resection. Endocr Rev. 2013;34:OR29-3
64. Libé R, Borget I, Ronchi CL, et al. Prognostic factors of advanced unresectable by stage 3and 4ENS@Tadrenocortical carcinomas (ACC). Endocr Abstr. 2013;32:OC4.3
65. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a revised TNM classification. Cancer. 2009;115:243-250
66. Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation. Eur J Cancer. 2010;46:713-719
67. Miller BS, Gauger PG, Hammer GD, Giordano TJ, Doherty GM. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg. 2010;395:955-961
68. Volante M, Sperone P, Bollito E, et al. Matrix metalloproteinasetype 2 expression in malignant adrenocortical tumors: diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Mod Pathol. 2006;19:1563-1569
69. Fenske W, Völker HU, Adam P, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer. 2009;16:919- 928
70. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189-2197
71. Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage 1 and 2 adrenocortical cancer. Eur Urol. 2010;57:873-878
72. Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg. 2010;34:1380-1385
73. Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open ad- renalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010;58:609-615
74. Lombardi CP, Raffaelli M, De Crea C, et al. Open versus endoscopic adrenalectomy in the treatment of localized (stage 1/2) adrenocortical carcinoma: Results of a multiinstitutional Italian survey. Surgery. 2012;152:1158-1164
75. Mir MC, Klink JC, Guillotreau J, et al. Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, high-volume center experience. Ann Surg Oncol. 2013; 20:1456-1461
76. Porpiglia F, Miller BS, Manfredi M,Fiori C, Doherty GM.Adebate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer. 2011;2:372-377
77. Jurowich C, Fassnacht M, Kroiss M, Deutschbein T, Germer CT, Reibetanz J. Is there a role for laparoscopic adrenalectomy in patients with suspected adrenocortical carcinoma? A critical appraisal of the literature. Horm Metab Res. 2013;45:130-136
78. Gaujoux S, Bertherat J, Dousset B, Groussin L. Laparoscopic adrenalectomy for adrenocortical carcinoma: A medico-surgical perspective. Ann Endocrinol (Paris). 2012;73:441-447
79. Reibetanz J, Jurowich C, Erdogan I, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255:363-369
80. Gaujoux S, Al-Ahmadie H, Allen PJ, et al. Resection of adrenocortical carcinoma liver metastasis: Is it justified? Ann Surg Oncol. 2012;19:2643-2651
81. Gaujoux S, Brennan MF. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery. 2012;152:123-132
82. Mihai R, Iacobone M, Makay O, et al. Outcome of operation in patients with adrenocortical cancer invading the inferiorvenacava - a European Society of Endocrine Surgeons (ESES) survey. Langenbecks Arch Surg. 2012;397:225-231
83. Kerkhofs TM, Verhoeven RH, Bonjer HJ, et al. Surgery for adrenocortical carcinoma in The Netherlands: Analysis of the national cancer registry data. Eur J Endocrinol. 2013;169:83-89
84. Lombardi CP, Raffaelli M, Boniardi M, et al. Adrenocortical carcinoma: Effect of hospital volume on patient outcome. Langenbecks Arch Surg. 2012;397:201-207
85. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: Clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20:941-950
86. Fassnacht M, Johanssen S, Fenske W, et al. Improved survival in patients with stage 2 adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010; 95:4925-4932
87. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356: 2372-2380
88. Huang H, Fojo T. Adjuvant mitotane for adrenocortical cancer - a recurring controversy. J Clin Endocrinol Metab. 2008;93:3730-3732
89. Grubbs EG, Callender GG, Xing Y, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17: 263-270
90. Berruti A, Fassnacht M, Baudin E, Hammer G, Haak H, Leboulleux S, Skogseid B, Allolio B, Terzolo M. Adjuvant therapy in patients with adrenocortical carcinoma: A position of an international panel. J Clin Oncol. 2010;28:e401-e402; author reply e403
91. Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:4501-4504
92. Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2011;80:1477-1484
93. Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:192-197
94. Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol. 2000;11:1281-1287
95. Cazejust J, De Baère T, Auperin A, et al. Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol. 2010;21:1527-1532
96. Ripley RT, Kemp CD, Davis JL, et al. Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol. 2011; 18:1972-1979
97. op den Winkel J, Pfannschmidt J, Muley T, et al. Metastatic adrenocortical carcinoma: Results of 56 pulmonary metastasectomies in 24 patients. Ann Thorac Surg. 2011;92:1965-1970
98. Kemp CD, Ripley RT, Mathur A, et al. Pulmonary resection for metastatic adrenocortical carcinoma: The National Cancer Institute experience. Ann Thorac Surg. 2011;92:1195-1200
99. Datrice NM, Langan RC, Ripley RT, et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 2012;105:709-713
100. Erdogan I, Deutschbein T, Jurowich C, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:181-191
101. Assié G, Antoni G, Tissier F, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2007; 92:148-154
102. Hermsen IG, Gelderblom H, Kievit J, Romijn JA, Haak HR. Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Eur J Endocrinol. 2008;158:911-919
103. De Francia S, Ardito A, Daffara F, et al. Mitotane treatment for adrenocortical carcinoma: An overview. Minerva Endocrinol. 2012;37:9-23
104. Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Brit J Cancer. 1994;69:947-951
105. Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001;92:1385-1392
106. Hermsen IG, FassnachtM,TerzoloM,et al. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: Results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab. 2011;96:1844-1851
107. Bourdeau I, MacKenzie-Feder J, Lacroix A. Recent advances in adrenocortical carcinoma in adults. Curr Opin Endocrinol Diabetes Obes. 2013;20:192-197
108. Glover AR, Ip JC, Zhao JT, Soon PS, Robinson BG, Sidhu SB. Current management options for recurrent adrenocortical carcinoma. Onco Targets Ther. 2013;6:635-643
109. Mauclère-Denost S, Leboulleux S, Borget I, et al. High-dose mitotane strategy in adrenocortical carcinoma: Prospective analysis of plasma mitotane measurement during the first 3 months of follow- up. Eur J Endocrinol. 2012;166:261-268
110. Kerkhofs T, Baudin E, Terzolo M, et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4759-4767
111. Kroiss M, Quinkler M, Johanssen S, et al. Sunitinib in refractory adrenocortical carcinoma: A phase 2, single-arm, open-label trial. J Clin Endocrinol Metab. 2012;97:3495-3503
112. Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: A multicenter phase II study. Endocr Relat Cancer. 2010;17:445-453
113. Polat B, Fassnacht M, Pfreundner L, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009;115:2816-2823
114. Samnotra V, Vassilopoulou-Sellin R, Fojo AT, et al.Aphase 2 trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). In: Proceedings from the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL. Abstract 15527
115. Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008;93:2057-2062
116. Kroiss M, Reuss M, Kuhner D, et al. Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells. Front Endocrinol (Lausanne). 2011;2:27
117. Mariniello B, Rosato A, Zuccolotto G, et al. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocr Relat Cancer. 2012;19:527-539
118. Xu YZ, Zhu Y, Shen ZJ, et al. Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: Potential for therapy. Endocrine. 2011;40:445-451
119. Wortmann S, Quinkler M, Ritter C, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010;162:349-356
120. Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012;166:451-458
121. García-Donas J, Polo SH, Guix M, et al. Phase II study of dovitinib in first line metastatic or (nonresectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03. In: Proceedings from the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago, IL. Abstract 4587
122. Naing A, Lorusso P, Fu S, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013;108:826-830
123. Fraenkel M, Gueorguiev M, Barak D, Salmon A, Grossman AB, Gross DJ. Everolimus therapy for progressive adrenocortical cancer. Endocrine. 2013;44:187-192
124. Hahner S, Kreissl MC, Fassnacht M, et al. [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97:914-922
125. Zhang H, Neely L, Lundgren K, et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer. 2010;126:1226-1234
126. Nilubol N, Zhang L, Shen M, et al. Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening. J Transl Med. 2012;10:198
127. Ferrero A, Sperone P, Ardito A, et al. Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno- cortical carcinoma. J Endocrinol Invest. 2013;36:148-152
128. Chacón R, Tossen G, Loria FS, Chacón M. Case 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. J Clin Oncol. 2005;23:1579-1580
129. Dobrosotskaya IY, Hammer GD, Schteingart DE, Maturen KE, Worden FP. Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma. Endocr Pract. 2011;17:e59-e62
130. Poli G, Guasti D, Rapizzi E, et al. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer. 2013;20:537-550
131. Hescot S, Slama A, Lombès A, et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer. 2013;20: 371-381
132. Stigliano A, Cerquetti L, Borro M, et al. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocr Relat Cancer. 2008;15:1-10
133. Lehmann TP, Wrzesiski T, Jagodziski PP. The effect of mitotane on viability, steroidogenesis and gene expression in NCI-H295R adrenocortical cells. Mol Med Rep. 2013;7:893-900
134. D'Avolio A, De Francia S, Basile V, et al. Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics. 2013;23:293-300
135. Terzolo M, Baudin AE, Ardito A, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol. 2013;169: 263-270
136. van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh Jd, Gelderblom H. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol. 2011;164:621-626
137. Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013;98:161-171
138. Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2011;75:585-591
139. Daffara F, De Francia S, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer. 2008;15:1043-1053
140. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006;13:535- 540